Literature DB >> 7226117

Combined chemotherapy and surgery in treatment of advanced germ-cell tumors.

D Vugrin, W F Whitmore, P C Sogani, M Bains, H W Herr, R B Golbey.   

Abstract

Forty-eight selected patients with GCT who were suspected of having residual disease after two or three chemotherapy inductions underwent an attempt at resection of this residual tumor. In 37 patients all gross disease was resected: 11 had malignant tissue, eight adult teratoma, and 18 no residual neoplasm, and 9, 7 and 17, respectively, remain free of disease. Patients in whom complete resection was not possible generally did poorly. Elevated serum tumor markers following the completion of preoperative chemotherapy indicated residual malignant disease and poor probability for complete resection. Twenty-nine percent of patients with negative preoperative markers had malignancy at the time of surgery, but disease was resectable in most of these patients. The key for success is, first, the response to chemotherapy and, second, complete resection of residual disease. It is recommended that patients with initially bulky metastases (diameter greater than 5 cm) be first managed by chemotherapy, employing successive close inductions, and subsequently explored with intent to resect residual disease. When the resected specimen shows malignant elements, the patients should receive additional inductions, otherwise, maintenance chemotherapy is employed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7226117     DOI: 10.1002/1097-0142(19810501)47:9<2228::aid-cncr2820470920>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Metastatic testicular germ cell tumour: the role of salvage surgery.

Authors:  K Suzuki; K Kurokawa; T Suzuki; S Jinbo; M Kobayashi; K Imai; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

2.  Germ cell tumor of the anterior mediastinum.

Authors:  E M Kabnick; C L Cooper; S Sobo; L L Alexander
Journal:  J Natl Med Assoc       Date:  1984-01       Impact factor: 1.798

Review 3.  Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?

Authors:  Stephen B Riggs; Earl F Burgess; Kris E Gaston; Caroline A Merwarth; Derek Raghavan
Journal:  Oncologist       Date:  2014-04-09

4.  Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines.

Authors:  A Harstrick; J Casper; H Köhne-Wömpner; H Wilke; H J Schmoll; H Poliwoda
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

5.  Comparison of two methods for tumour-targeting peptide modification of liposomes.

Authors:  Shi-Qi Huang; Han-Ming Zhang; Yi-Cong Zhang; Lu-Yao Wang; Zhi-Rong Zhang; Ling Zhang
Journal:  Acta Pharmacol Sin       Date:  2022-10-21       Impact factor: 7.169

6.  VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

Authors:  L H Einhorn
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Size and status of metastases after inductive chemotherapy of germ-cell tumors. Indication for salvage operation.

Authors:  N Jaeger; L Weissbach; R Bussar-Maatz
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 8.  Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis.

Authors:  J P Donohue; E P Fox; S D Williams; P J Loehrer; T M Ulbright; L H Einhorn; T D Weathers
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

9.  Primary malignant mediastinal germ cell tumours: improved prognosis with platinum-based chemotherapy and surgery.

Authors:  W J Childs; P Goldstraw; J E Nicholls; D P Dearnaley; A Horwich
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

10.  Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma.

Authors:  D Tait; M J Peckham; W F Hendry; P Goldstraw
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.